Kornimate/medical-research-clean huggingface dataset:
the benefits of virtual reality in the care of elderly people with psychomotor disadaptation syndrome

Conditions: Psychomotor Disadaptation Syndrome

Summary: psychomotor disadaptation syndrome (pmds) is characterised by a deterioration in postural function, gait and psychomotor automatisms in the elderly. it is often associated with falls and can manifest itself as retropulsion, gait abnormalities, neurological disorders and psycho-behavioural problems. for the majority of these patients, a stay in a geriatric medical and rehabilitation centre is necessary, enabling an objective assessment of these disorders and multi-professional care, including physiotherapists, occupational therapists and adapted physical activity teachers, aimed at restoring safe movement and motor independence. however, rehabilitation relies on traditional exercises that are limited, repetitive and sometimes far removed from everyday activities. technological innovations such as virtual reality (vr) offer opportunities to improve care by creating immersive environments that reproduce real-life situations. vr could thus help to rehabilitate the motor problems associated with ms. the aim of the vir-age project is to study the clinical benefits of vr in the rehabilitation of hospitalised elderly people suffering from pmds in terms of functional deficits, particularly motor deficits. the study will take place at the centre gériatrique champmaillot of the chu dijon bourgogne. a total of 50 patients with spdm will take part. the total duration of your participation is 5 weeks.


Eligibility criteria:
inclusion criteria: * person who has given written consent * person aged ≥ 65 years; * with a proven diagnosis of motor maladjustment syndrome; * hospitalised in a geriatric care unit; * able to understand a simple instruction and answer a closed question; exclusion criteria: * person not affiliated to or not benefiting from a social security scheme * person subject to a legal protection measure (curatorship, guardianship) * person subject to a judicial protection measure * an adult who is incapable or unable to give consent * persons with epilepsy, kinetosis or known claustrophobia persons unable to understand simple instructions for carrying out tests * anyone with a severe visual and/or hearing impairment * any person with a behavioural disorder (agitation, aggressiveness) * any person with a severe walking or balance problem that makes motor exercises unsuitable * anyone with a pathology, injury, wound or severe deformity to the head or cervical spine * any person suffering from severe vertigo, diagnosed at the discretion of the investigating doctor * inability to use arm for pointing * persons susceptible to migraines * non-french speakers * anyone with an inter-pupillary distance outside the range of possible helmet adjustments
case control psychological autopsy of suicide

Conditions: Suicide; Fatal Suicide; Non Fatal Suicidal Behavior

Summary: suicide is a leading cause of death worldwide, and identifying risk factors has been considered as the key initiative of suicide prevention. considering that, the study aimed to explore the factors leading towards suicide in pakistan through case-control psychological autopsy of suicide. also, the study aimed to translate, adapt and validate american association of suicidology (aas) semi-structured interview for psychological autopsy (generic version, 2018).


Eligibility criteria:
inclusion criteria: * the age of the deceased by suicide and living controls will range from 10 to 35 years. * the key informants will be of 18 years of age and above without any learning * disability. * the key informants will be a close family member or immediate friend. * only suicides took place in 2019 to september 2021. exclusion criteria: * if contact was deemed to pose a risk to the safety of the researcher (likely intoxication; history of or potential for violence). * informants who are not willing to give written informed consent will be excluded from the study. * informants who are taking any psychological help in the past and present will be excluded from the study.

Keywords: cases controls
prp for rotator cuff tears

Conditions: Rotator Cuff Tears

Summary: regenerative medicine, specifically orthobiologics is a hot topic in the community and in sports medicine. riding the hype curve of a new treatment can be great when offering new procedures to patients. however, as the excitement regarding potential benefits of orthobiologics grows, it is valuable to grow the body of literature on their safety and efficacy in various musculoskeletal conditions. furthering the body of data regarding which musculoskeletal conditions may benefit most from these treatments and which may not can help guide physicians on when to incorporate orthobiologics into clinical practice. more robust data can help physicians guide patients and patient expectations when discussing treatment options. platelet rich plasma (prp) in musculoskeletal medicine is most commonly used to treat tendinopathies and degenerative joint disease. the american medical society for sports medicine released a position statement in november of 2021 summarizing meta-analysis and systemic review data evaluating efficacy and major adverse events of prp for tendinopathy and osteoarthritis1. at this time, the most robust data exists for lateral epicondylopathy as multiple randomized controlled trials demonstrate positive response to prp. gluteus medius tendinopathy and plantar fasciaopathy similarly have positive data. in achilles tendinopathy, well designed rcts have shown no difference between prp and saline injections. these data should help guide physicians in responsible use and patient counseling. data from hurley et al. suggest prp may augment rotator cuff repair with improved rates of healing and reduced overall pain. however, there are limited high quality studies on the efficacy of prp alone in partial rotator cuff tear. partial rotator cuff tear is a common musculoskeletal complaint that can be treated with conservative measures such as physical therapy and corticosteroid injection. it can also be treated with surgical intervention if those modalities provide incomplete or inadequate pain relief and functional restoration. this study aims to evaluate if prp is an efficacious treatment modality for partial rotator cuff tear.


Eligibility criteria:
inclusion criteria: * adult patients with symptomatic partial rotator cuff tear of one rotator cuff tendon diagnosed on imaging with mri * adult patients with symptomatic partial rotator cuff tear of one rotator cuff tendon diagnosed on imaging with ultrasound. exclusion criteria: * patients who have had any an intervention within the past three months (csi, prp, prolotherapy) * patient with previous surgical interventions on the same rotator cuff. * patients on aspirin who cannot discontinue medication 1 week prior and 6 weeks after the procedure. * patients who decline to discontinue anti-inflammatory medications or supplements for 1 week prior and 6 weeks after the procedure. * any procedure that utilized less than 2-3 cc of prp * patients that require blood to be drawn twice on the same day.

Keywords: prp
the influence of the nutritional status of women between 30 and 45 years of age on the condition of the skin and body composition

Conditions: Skin Condition; Body Composition

Summary: goal is to investigate the differences in skin condition and body composition among women with different dietary habits aged 30-45 years. study will be focused onto sub-groups of female subjects following omnivorous, vegetarian or vegan diet.

investigators will investigate differences among female subjects aged 30-45 years following one of the following diet for at least 3 years: * vegan * vegetarian * omnivorous study will focus into the differences in dermal protein density and dermal thickness, skin hydration and trans-epidermal water loss. study will focus also into body composition, specifically into % of body fat and % of lean body weight.

Eligibility criteria:
inclusion criteria: * women * aged 30-45 years * vegan or vegetarian or omnivorous diet for at least 3 years, * body mass index (bmi) between 18.5 and 25. exclusion criteria: * smoking or have smoked in the past (quit less than 3 years ago), * pregnancy or breastfeeding, * pre-menopause * medications that increase skin dryness (e.g. retinoids), * visiting solariums, * visiting of the fitness center more than 3 times a week, * regular consumption of protein supplements (including food supplements with collagen), * chronic and acute skin diseases, * chronic and acute diseases of the gastrointestinal tract (e.g. celiac disease), * lactose intolerance, * various diets (e.g. health, slimming), * damaged skin in the test area (inner forearm), * hyperhidrosis or increased sweating, * diseases that cause a chronically damaged skin barrier (e.g. atopic dermatitis, ichthyosis), * cancer diseases, * pacemaker.
high dose vitamin d vs standard dose vitamin d study

Conditions: Breast Cancer

Summary: this study is being done to look at the difference, if there is a difference between two different doses of vitamin d and the reduction of joint/muscle pain (arthralgia)that is caused by taking anti-estrogen medications (aromatase inhibitors) by breast cancer patients. the investigators hope to learn if taking a higher dose of vitamin d is a good way to prevent aromatase inhibitor arthralgia (aia).

treatments with anti-estrogen agents for hormone receptor positive breast cancer is the most efficacious of systemic therapies, with aromatase inhibitors (ai's) being considered the most active anti-estrogen therapy in early stage breast cancer. but, use of these treatments has been shown to cause musculoskeletal (joint/muscle) side effects that sometimes cause patients to discontinue the use of them. also, vitamin d deficiency is a well know cause of a wide array of musculoskeletal issues. there is evidence that vitamin d supplementation may help prevent arthralgia while on ai's. therefore, the investigators want to see if giving a higher dose of vitamin d could decrease the incidence of aia as compared to a standard dose of vitamin d. the investigators believe that this could possibly result in patients continued treatment with ai therapy for hormone receptor positive breast cancer.

Eligibility criteria:
inclusion criteria: * all participants must be female and at least 21 years of age * signed informed consent * patients must have had histologically confirmed stage i-iii breast carcinoma that is positive for estrogen receptor (er) and/or progesterone receptor (pr). * post-menopausal * beginning adjuvant aromatase inhibitor therapy, with no previous use within the last 6 weeks * bisphosphonates are allowed at the treating investigator¡¦s discretion * performance status (who/ecog scale) 0-2. exclusion criteria: * history of kidney stones * hypercalcemia at baseline, defined as any corrected calcium greater than the laboratory's normal parameters * history of either symptomatic hypercalcemia or hyperparathyroidism, at the treating investigator's discretion * baseline vitamin d level greater than 50 ng/ml * inability or unwillingness to comply with, or follow study procedures. * currently taking phenytoin or phenobarbital -7 currently taking cholestyramine or orlistat * malabsorption syndrome, such as crohn's disease prohibited therapies: patients may not take additional calcium and vitamin d aside from the study medications. patients who are on cholestyramine or orlistat will not be allowed on the trial. also, patients who are taking phenytoin or phenobarbital are not allowed on the trial either because of interaction between vitamin d and anti-epileptic medications.

Keywords: breast cancer hormone receptor positive vitamin d
breath analysis to diagnose lung cancer

Conditions: Lung Cancer

Summary: determination of volatile organic compounds to discriminate patients with lung cancer from healthy smokers and non-smokers healthy subjects.


Eligibility criteria:
inclusion criteria: * patients with histologically proven lung cancer controls: * healthy smoker or non-smoker subjects * without respiratory diseases excepted chronic obstructive pulmonary disease. exclusion criteria: * history of cancer other than lung cancer within 5 years before inclusion * oral or facial malformation * incomprehension of maneuvers for the collection

Keywords: lung cancer diagnosis volatile organic compounds
irinotecan, capecitabine and avastin for metastatic colorectal cancer as salvage treatment

Conditions: Metastatic Colorectal Cancer

Summary: this study will evaluate the efficacy of irinotecan,capecitabine and avastin combination in patients with no response to previous treatment with 5-fluorouracil,leucovorin,eloxatin and avastin.

the aim of this phase ii study is to evaluate the efficacy of the combination xeliri/avastin in patients with mcrc, who have progressed in first line treatment with folfox/avastin. for avastin was selected the dosing schedule of the trials tree 1 and 2 \[17\], where avastin was combined with capecitabine and oxaliplatin in a three weeks schedule and with adaptation of the dose in the 7,5 mg/kg

Eligibility criteria:
inclusion criteria: * histologically confirmed locally advanced or metastatic colorectal cancer * measurable or evaluable disease according to the response evaluation criteria in solid tumors * ecog performance status ≤ 2 * age 18 - 72 years * patients who progress after 1st line therapy with folfox/avastin * adequate liver (bilirubin ≤ 1.5 upper normal limit, sgot/sgpt ≤ 4 upper normal limit, alp ≤ 2.5 upper normal limit) renal (creatinine ≤ 1.5 upper normal limit) and bone marrow (anc ≥ 1,500/mm3, plt ≥100,000/mm3) function * patients must be able to understand the nature of this study * written informed consent exclusion criteria: * history of serious cardiac disease (unstable angina, congestive heart failure,uncontrolled cardiac arrhythmias) * history of myocardial infarction or stroke within 6 months * clinically significant peripheral vascular disease * history of abdominal fistula, gastrointestinal perforation or intraabdominal abscess within 28 days prior to day 0 * major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to day 1 * presence of central nervous system or brain metastasis * evidence of bleeding diathesis or coagulopathy * blood pressure \> 150/100 mmhg * pregnant or lactating woman * life expectancy \< 3 months * previous radiotherapy within the last 4 weeks or \> 25% of bone marrow * metastatic infiltration of the liver \> 50% * patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or total colectomy * active infection requiring antibiotics on day 1 * second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer * psychiatric illness or social situation that would preclude study compliance

Keywords: colorectal cancer bevacizumab xeliri
study on the effect of fish oil and appetite

Conditions: Obesity; Cachexia

Summary: 20 normal-weight healthy subjects (10 males, 10 females) were in two periods given 10 of 0.5-ml capsules/day of fish oil and soybean oil for 3 weeks. in the end of each period they were given a standard breakfast and asked to report their appetite on visual analogue scales (vas) immediately before and after the meal. the results were analyzed in accordance with the paired design under consideration of both supplement sequence and gender.

in a randomized cross-over design, 20 normal-weight healthy subjects (10 males, 10 females) were given 10 of 0.5-ml capsules/day of fish oil and soybean oil for 3 weeks. in the end of each period they were given a standard breakfast and asked to report their appetite on visual analogue scales (vas) immediately before and after the meal. the results were analyzed in accordance with the paired design under consideration of both supplement sequence and gender.

Eligibility criteria:
inclusion criteria: * normal weight (18.5\<bmi\<25 kg/m2). * healthy. exclusion criteria: * subjects taking medication that could influence appetite. * subjects with special nutritional needs e.g. pregnant and lactating, seriously ill or old people. * subjects that had had fish oil-supplements for four weeks prior to the intervention period.

Keywords: appetite fish oil long-chain n-3 fatty acids
comparative validation of the triptorelin test for the diagnosis of cpp in girls

Conditions: Central Precocious Puberty; Sexual Precocity

Summary: the aim of the study is to determine the specificity, sensitivity and diagnostic efficiency of the triptorelin test in the assessment of cpp compared to gnrh test as gold standard. hypothesis: aqueous triptorelin acetate is so efficient as gnrh to cpp assessment. study population are girls with suspicious clinical features of precocious puberty

gnrh stimulation is the gold standard to distinguish between isolated premature thelarche (pt) and cpp. however, intravenous gnrh for testing is not fully available in all countries. to evaluate the diagnostic accuracy of a novel triptorelin-test in the assessment of cpp compared to the gnrh test, a validation study was performed. girls who presented thelarche with accelerated growth and/or advanced bone age were included. all girls underwent the two tests in a randomized order. cpp was ascertained according to lh response under gnrh (gold standard test).

Eligibility criteria:
inclusion criteria: * premature thelarche and/or * accelerated growth velocity (above 90 percentile) * advanced bone age at least 1.5 year in relation to chronological age. exclusion criteria: * contact with sources of exogenous estrogens in the last four months previous to evaluation, * suspicion of peripheral precocious puberty, * previous central nervous system illness or suspicion of organic central precocious puberty.

Keywords: triptorelin acetate precocious puberty premature thelarche gnrh analog diagnostic validation study
study of s-3304 in patients with locally advanced non-small cell lung cancer

Conditions: Non Small Cell Lung Cancer; Lung Cancer; Stage IIIA Non Small Cell Lung Cancer; Stage IIIB Non Small Cell Lung Cancer

Summary: a study to measure the safety and effectiveness of s-3304 when given in combination with conventional chemo-radiation therapy in patients with locally advanced non-small cell lung cancer.

a two part study to evaluate the safety and efficacy of s-3304 in combination with standard therapy in patients with locally advanced non-small cell lung cancer. the first part of the study is a phase i design to evaluate the maximum tolerated dose of s-3304 when given in combination with radiation and paclitaxel/carboplatin chemotherapy that is appropriate for further evaluation. the second part of the study is a randomized phase ii design to evaluate the efficacy of recommended s-3304 dose in combination with chemo-radiation.

Eligibility criteria:
inclusion criteria * newly diagnosed non-small cell lung cancer of stage iiia non-resectable or of stage iiib without pleural effusion * ecog performance status 0-1 * adequate organ function * clinically indicated and able to receive conventional chemoradiation therapy exclusion criteria * patients with prior history of cancer, other than basal cell carcinoma after appropriate treatment, or prior systemic chemotherapy treatment * patients with other serious intercurrent illness including hiv/aids, or contraindicated for paclitaxel/carboplatin or thoracic irradiation treatment

Keywords: lung cancer lung carcinoma non small cell lung cancer stage iiia non small cell lung cancer stage iiib non small cell lung cancer nsclc stage iii chemotherapy radiation chemoradiation matrix metalloproteinases neovascularization antiangiogenesis type iv collagenases unresectable locally advanced non-small cell lung cancer
patupilone versus doxorubicin in patients with ovarian, primary fallopian, or peritoneal cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms

Summary: the objective of this study is to assess the safety and efficacy of patupilone compared to pegylated liposomal doxorubicin. additionally, this study will assess the ability of patupilone to extend the survival time and potential beneficial effects in women who have nonresponsive or recurrent ovarian, primary fallopian, or primary peritoneal cancer.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * confirmed diagnosis of ovarian, fallopian or peritoneal cancer * no more than three chemotherapy regimens * most recent regimen must have been platinum based exclusion criteria: * have an unresolved bowel obstruction * have had previous chemotherapy within 3 weeks * recovering from any surgery for any cause other protocol-defined inclusion/exclusion criteria will apply.

Keywords: epithelial ovarian cancer fallopian tube cancer peritoneal cancer primary cancer recurrent cancer doxorubicin taxane chemotherapy platinum chemotherapy patupilone taxane platinum resistant
a study of durvalumab as consolidation therapy in non-small cell lung cancer patients

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: this is a phase iii, randomised, double-blind, placebo-controlled, multicentre study assessing the efficacy and safety of durvalumab compared with placebo, as consolidation therapy in patients with locally advanced, unresectable, non-small cell lung cancer (stage iii), who have not progressed following definitive, platinum-based, chemoradiation therapy.

approximately 400 patients will be randomized in a 2:1 to receive treatment with durvalumab or placebo therapy. the primary objective of this study is to assess the efficacy of durvalumab treatment compared with placebo in terms of pfs.

Eligibility criteria:
inclusion criteria: 1. age≥18 years 2. documented nsclc and present with locally advanced, unresectable (stage iii) disease; 3. receipt of concurrent or sequential chemoradiation therapy, 4. no progression following definitive, platinum-based, concurrent or sequential chemoradiation therapy 5. world health organization (who) ps of 0 or 1; 6. no prior exposure to any anti ctla-4, anti-pd-1, anti-pd-l1, or anti pd l2 antibodies, excluding therapeutic anticancer vaccines 7. adequate organ and marrow function required 8. life expectancy of at least 12 weeks 9. tumor pd-l1 status, with the ventana sp263 pd-l1 ihc assay determined by a reference laboratory, must be known prior to randomization. 10. tumour sample requirements are as follows: provision of a tumour tissue sample (newly acquired sample \<=3 months old is preferred, but an archived sample \<=6 months old is acceptable) in a quantity sufficient to allow for analysis. exclusion criteria: 1. history of allogeneic organ transplantation, or another primary malignancy, or active primary immunodeficiency. 2. active or prior documented autoimmune or inflammatory disorders 3. uncontrolled intercurrent illness that would limit compliance with study requirement, substantially increase risk of incurring aes, or compromise the ability of the patient to give written informed consent 4. active infection including tuberculosis hepatitis b hepatitis c (hcv), or human immunodeficiency virus (positive human immunodeficiency virus \[hiv\] 1/2 antibodies). 5. mixed small cell and nsclc histology, sarcomatoid variant 6. any unresolved toxicity national cancer institute (nci) common terminology criteria for adverse events (ctcae) grade ≥2 from the prior chemoradiation therapy. 7. receipt of live attenuated vaccine within 30 days prior to the first dose of ip. 8. major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of ip.

Keywords: nsclc double-blind pd-l1 medi4736 durvalumab pfs os